The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes
- PMID: 28675686
- PMCID: PMC5810921
- DOI: 10.1111/dom.13052
The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes
Abstract
For patients with type 1 diabetes, closed-loop delivery systems (CLS) combining an insulin pump, a glucose sensor and a dosing algorithm allowing a dynamic hormonal infusion have been shown to improve glucose control when compared with conventional therapy. Yet, reducing glucose excursion and simplification of prandial insulin doses remain a challenge. The objective of this literature review is to examine current meal-time strategies in the context of automated delivery systems in adults and children with type 1 diabetes. Current challenges and considerations for post-meal glucose control will also be discussed. Despite promising results with meal detection, the fully automated CLS has yet failed to provide comparable glucose control to CLS with carbohydrate-matched bolus in the post-meal period. The latter strategy has been efficient in controlling post-meal glucose using different algorithms and in various settings, but at the cost of a meal carbohydrate counting burden for patients. Further improvements in meal detection algorithms or simplified meal-priming boluses may represent interesting avenues. The greatest challenges remain in regards to the pharmacokinetic and dynamic profiles of available rapid insulins as well as sensor accuracy and lag-time. New and upcoming faster acting insulins could provide important benefits. Multi-hormone CLS (eg, dual-hormone combining insulin with glucagon or pramlintide) and adjunctive therapy (eg, GLP-1 and SGLT2 inhibitors) also represent promising options. Meal glucose control with the artificial pancreas remains an important challenge for which the optimal strategy is still to be determined.
Keywords: artificial pancreas; closed-loop; glycaemic control; insulin delivery; insulin therapy; type 1 diabetes.
© 2017 John Wiley & Sons Ltd.
Conflict of interest statement
RRL has received consultant/speaker honorariums and/or his institution received grants from Astra-Zeneca, Becton Dickinson, Bohringer, Eli Lilly, Janssen, Insulet, Lifescan, Medtronic, Merck, Novartis, Neomed, Novo-Nordisk, Roche, Sanofi-Aventis, Takeda and Valeant. LL has received consultant/speaker honorariums and/or his institution received grants from Eli Lilly, Medtronic, Novo-Nordisk, Merck and Sanofi. No other competing financial interests were reported.
References
-
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986. - PubMed
-
- Canadian Diabetes Association Clinical Practice Guidelines Expert C. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(Suppl 1):S1–S212. - PubMed
-
- Savard V, Gingras V, Leroux C, et al. Treatment of Hypoglycemia in Adult Patients with Type 1 Diabetes: An Observational Study. Can J Diabetes. 2016;40(4):318–323. - PubMed
-
- Brazeau AS, Mircescu H, Desjardins K, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract. 2013;99(1):19–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
